Loading...
Market
Additional legal actions against McKinsey for opioid advisory work by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Public court records and announcements from the Department of Justice
Story
McKinsey to Pay $650 Million to Settle DOJ Opioid Probe; Ex-Partner Pleads Guilty
Dec 13, 2024, 03:19 PM
McKinsey & Company has agreed to pay $650 million to settle U.S. Department of Justice criminal and civil investigations into its advisory work with opioid manufacturers, including Purdue Pharma, maker of OxyContin. The consulting firm accepted responsibility for its role in advising opioid producers on how to boost sales, including 'turbocharging' OxyContin sales, which prosecutors said contributed to the opioid epidemic. McKinsey entered into a five-year deferred prosecution agreement to resolve criminal charges, including conspiring with Purdue Pharma and others to aid and abet misbranding of prescription drugs. A former senior partner will plead guilty to obstruction of justice.
View original story
Similar markets
U.S. Department of Justice • 25%
Federal Trade Commission • 25%
Securities and Exchange Commission • 25%
Other • 25%
No • 50%
Yes • 50%
$1.5 billion to $2 billion • 25%
$1 billion to $1.5 billion • 25%
More than $2 billion • 25%
Less than $1 billion • 25%
McKinsey & Company • 25%
Other • 25%
Boston Consulting Group • 25%
Bain & Company • 25%
Reach new settlements with other firms • 25%
No significant actions • 25%
Rebrand or restructure • 25%
File for bankruptcy again • 25%
Endo International • 25%
Other • 25%
Teva Pharmaceuticals • 25%
Johnson & Johnson • 25%